Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05051384

Superb Microvascular Intraocular Tumor Imaging Study (SMITIS)

Using the Superb Microvascular Imaging Method in the Diagnosis of Intraocular Tumors (SMITIS)

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The diagnosis and monitoring of intraocular tumors are based on multimodal imaging in addition to the clinical examination (ultra-widefield retinal imaging, echography, angiography). Nevertheless, it may be difficult in cases of retinal hemorrhage, small tumor size or atypical presentation. The study of microvascular flow (Superb Microvascular Imaging, SMI) of intraocular tumors could improve the confidence of differential diagnosis when evaluating these suspicious lesions, or even determine whether a lesion is benign or malignant by describing the vascularization of the lesion. The investigators propose to study the microvascular flow patterns of intraocular tumors prior to proton therapy.

Detailed description

The ultrasound equipment available in ophthalmology does not have Doppler technology and does not allow the study of the vascularization and microvascularization of intraocular lesions. The interest in the system used in this study is to import SMI into ophthalmology to study tumor microvascularization. The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTDoppler technologyThe study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors

Timeline

Start date
2022-04-27
Primary completion
2023-04-27
Completion
2026-01-18
First posted
2021-09-21
Last updated
2025-12-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05051384. Inclusion in this directory is not an endorsement.